<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104124">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01748942</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00008071</org_study_id>
    <secondary_id>NCI-2012-02780</secondary_id>
    <secondary_id>CPC-12095-L</secondary_id>
    <secondary_id>CR00021919</secondary_id>
    <secondary_id>IRB00008071</secondary_id>
    <secondary_id>P30CA069533</secondary_id>
    <nct_id>NCT01748942</nct_id>
  </id_info>
  <brief_title>Dexamethasone in Reducing Oral Pain and Dry Mouth After Surgery in Patients With Oropharyngeal Cancer</brief_title>
  <official_title>A Randomized, Placebo Controlled, Double Blinded Study of Corticosteroid Treatment for the Reduction of Postoperative Pain Following Transoral Robotic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized pilot clinical trial studies dexamethasone in reducing oral pain and dry
      mouth after surgery in patients with oropharyngeal cancer. Dexamethasone may help lower pain
      and dry mouth caused by surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To prospectively determine if a longer 4-day course of dexamethasone (or equivalent) for
      the management of postoperative pain and dysphagia following transoral robotic surgery
      (TORS) is superior to the current standard of a single injection of dexamethasone 10 mg.

      SECONDARY OBJECTIVES:

      I. Determine the effect of postoperative corticosteroids on postoperative dysphagia
      following TORS.

      II. Determine the effect of postoperative corticosteroids on length of hospital stay
      following TORS.

      III. Determine the complications associated with postoperative corticosteroid use after
      TORS.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients receive dexamethasone intravenously (IV) at the time of surgery and orally
      (PO) every 8 hours for up to 4 days following surgery.

      ARM II: Patients receive dexamethasone IV at the time of surgery and placebo PO every 8
      hours for up to 4 days following surgery.

      After completion of study treatment, patients are followed up for up to 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2012</start_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain visual analogue scale (VAS) score measured at 10-point scale</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>A descriptive time plot of VAS scores will be produced for all enrolled subjects, with loess curve fitted separately for the experimental and control groups. A linear mixed effects model will be used to compare the pain VAS scores between the experimental and control groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complications associated with postoperative corticosteroid use after TORS</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>A descriptive statistical analysis will be conducted on complications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eating Assessment Tool (EAT)-10 scores</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>A descriptive time plot will be produced for EAT-10 scores using baseline and postoperative measurements on days 3 and day 7-21. Descriptive statistical analyses will be conducted for a summary of EAT-10 scores at baseline, days 3 and day 7-21 after surgery. A linear mixed effects model will be used to compare the EAT-10 scores between the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay (number of days between the date of surgery and date of discharge)</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>Kaplan-Meier functions will be fitted to compare the length of hospital stay between the experimental and control groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Dysphagia</condition>
  <condition>Pain</condition>
  <condition>Stage I Oropharyngeal Squamous Cell Carcinoma</condition>
  <condition>Stage II Oropharyngeal Squamous Cell Carcinoma</condition>
  <condition>Stage III Oropharyngeal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm I (treatment)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive dexamethasone IV at the time of surgery and PO every 8 hours for up to 4 days following surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (control)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive dexamethasone IV at the time of surgery and placebo PO every 8 hours for up to 4 days following surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (treatment)</arm_group_label>
    <arm_group_label>Arm II (control)</arm_group_label>
    <other_name>Aacidexam</other_name>
    <other_name>Adexone</other_name>
    <other_name>Aknichthol Dexa</other_name>
    <other_name>Alba-Dex</other_name>
    <other_name>Alin</other_name>
    <other_name>Alin Depot</other_name>
    <other_name>Alin Oftalmico</other_name>
    <other_name>Amplidermis</other_name>
    <other_name>Anemul mono</other_name>
    <other_name>Auricularum</other_name>
    <other_name>Auxiloson</other_name>
    <other_name>Baycuten</other_name>
    <other_name>Baycuten N</other_name>
    <other_name>Cortidexason</other_name>
    <other_name>Cortisumman</other_name>
    <other_name>Decacort</other_name>
    <other_name>Decadrol</other_name>
    <other_name>Decadron</other_name>
    <other_name>Decalix</other_name>
    <other_name>Decameth</other_name>
    <other_name>Decasone R.p.</other_name>
    <other_name>Dectancyl</other_name>
    <other_name>Dekacort</other_name>
    <other_name>Deltafluorene</other_name>
    <other_name>Deronil</other_name>
    <other_name>Desamethasone</other_name>
    <other_name>Desameton</other_name>
    <other_name>Dexa-Mamallet</other_name>
    <other_name>Dexa-Rhinosan</other_name>
    <other_name>Dexa-Scheroson</other_name>
    <other_name>Dexa-sine</other_name>
    <other_name>Dexacortal</other_name>
    <other_name>Dexacortin</other_name>
    <other_name>Dexafarma</other_name>
    <other_name>Dexafluorene</other_name>
    <other_name>Dexalocal</other_name>
    <other_name>Dexamecortin</other_name>
    <other_name>Dexameth</other_name>
    <other_name>Dexamethasonum</other_name>
    <other_name>Dexamonozon</other_name>
    <other_name>Dexapos</other_name>
    <other_name>Dexinoral</other_name>
    <other_name>Dexone</other_name>
    <other_name>Dinormon</other_name>
    <other_name>Fluorodelta</other_name>
    <other_name>Fortecortin</other_name>
    <other_name>Gammacorten</other_name>
    <other_name>Hexadecadrol</other_name>
    <other_name>Hexadrol</other_name>
    <other_name>Lokalison-F</other_name>
    <other_name>Loverine</other_name>
    <other_name>Methylfluorprednisolone</other_name>
    <other_name>Millicorten</other_name>
    <other_name>Mymethasone</other_name>
    <other_name>Orgadrone</other_name>
    <other_name>Spersadex</other_name>
    <other_name>Visumetazone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (treatment)</arm_group_label>
    <other_name>Aacidexam</other_name>
    <other_name>Adexone</other_name>
    <other_name>Aknichthol Dexa</other_name>
    <other_name>Alba-Dex</other_name>
    <other_name>Alin</other_name>
    <other_name>Alin Depot</other_name>
    <other_name>Alin Oftalmico</other_name>
    <other_name>Amplidermis</other_name>
    <other_name>Anemul mono</other_name>
    <other_name>Auricularum</other_name>
    <other_name>Auxiloson</other_name>
    <other_name>Baycuten</other_name>
    <other_name>Baycuten N</other_name>
    <other_name>Cortidexason</other_name>
    <other_name>Cortisumman</other_name>
    <other_name>Decacort</other_name>
    <other_name>Decadrol</other_name>
    <other_name>Decadron</other_name>
    <other_name>Decalix</other_name>
    <other_name>Decameth</other_name>
    <other_name>Decasone R.p.</other_name>
    <other_name>Dectancyl</other_name>
    <other_name>Dekacort</other_name>
    <other_name>Deltafluorene</other_name>
    <other_name>Deronil</other_name>
    <other_name>Desamethasone</other_name>
    <other_name>Desameton</other_name>
    <other_name>Dexa-Mamallet</other_name>
    <other_name>Dexa-Rhinosan</other_name>
    <other_name>Dexa-Scheroson</other_name>
    <other_name>Dexa-sine</other_name>
    <other_name>Dexacortal</other_name>
    <other_name>Dexacortin</other_name>
    <other_name>Dexafarma</other_name>
    <other_name>Dexafluorene</other_name>
    <other_name>Dexalocal</other_name>
    <other_name>Dexamecortin</other_name>
    <other_name>Dexameth</other_name>
    <other_name>Dexamethasonum</other_name>
    <other_name>Dexamonozon</other_name>
    <other_name>Dexapos</other_name>
    <other_name>Dexinoral</other_name>
    <other_name>Dexone</other_name>
    <other_name>Dinormon</other_name>
    <other_name>Fluorodelta</other_name>
    <other_name>Fortecortin</other_name>
    <other_name>Gammacorten</other_name>
    <other_name>Hexadecadrol</other_name>
    <other_name>Hexadrol</other_name>
    <other_name>Lokalison-F</other_name>
    <other_name>Loverine</other_name>
    <other_name>Methylfluorprednisolone</other_name>
    <other_name>Millicorten</other_name>
    <other_name>Mymethasone</other_name>
    <other_name>Orgadrone</other_name>
    <other_name>Spersadex</other_name>
    <other_name>Visumetazone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm II (control)</arm_group_label>
    <other_name>placebo therapy</other_name>
    <other_name>PLCB</other_name>
    <other_name>sham therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (treatment)</arm_group_label>
    <arm_group_label>Arm II (control)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (treatment)</arm_group_label>
    <arm_group_label>Arm II (control)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transoral Robotic Surgery</intervention_name>
    <description>Undergo TORS</description>
    <arm_group_label>Arm I (treatment)</arm_group_label>
    <arm_group_label>Arm II (control)</arm_group_label>
    <other_name>TORS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be diagnosed with oropharyngeal squamous cell carcinoma (SCC) that are
             surgical candidates

          -  Macroscopic resection of the tumor via TORS must be planned with curative intent

          -  Patient must be willing to remain on corticosteroid therapy for 4 days
             postoperatively

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Patients with known distant metastases or other malignancies

          -  Patients with a history of allergy or adverse reaction to corticosteroids

          -  Patients with a history of diabetes

          -  Patients with fasting capillary blood glucose of &gt; 140 on the day of surgery

          -  Patients on chronic corticosteroids

          -  Chronic alcohol abuse (&gt; 6 alcoholic beverages daily)

          -  Patients with a history of severe chronic pain on high dose narcotics (&gt; 25 mg of
             oxycodone or equivalent daily) preceding diagnosis of cancer

          -  Patients taking significant cytochrome P450 family 3, subfamily A, polypeptide 4
             (CYP3A4) inhibitors or inducers, i.e. protease inhibitors (ritonavir, nelfinavir,
             etc), clarithromycin, ketoconazole, fluconazole, verapamil, diltiazem, carbamazepine,
             phenytoin, phenobarbital, Rifampin, efavirenz, nevirapine

          -  Patients who have received any investigational medication within 6 weeks of
             enrollment, or who are scheduled to receive an investigational drug during the course
             of the study

          -  Patients who will undergo complex head and neck surgery in addition to the TORS
             procedure requiring reconstruction with a free flap

          -  Patients who have had any previous head and neck surgery that has affected
             swallowing, voice or speech or who have had previous radiation to the head or neck

          -  Patients who have any confounding medical or neurological conditions that have the
             potential to affect cognition, speech or swallowing function; i.e. stroke,
             neurodegenerative disease, neuromuscular movement disorders, head injury, etcetera

          -  Psychiatric illness/social situations that would limit compliance with study
             requirements

          -  Excluded patients will be allowed to participate in the trial on an observational
             basis only
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Clayburgh</last_name>
    <role>Principal Investigator</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OHSU Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 16, 2017</lastchanged_date>
  <firstreceived_date>December 11, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
